|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zornosa C, Vandergrift JL, Kalemkerian GP,
Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA,
Niland JC, et al: First-line systemic therapy practice patterns and
concordance with NCCN guidelines for patients diagnosed with
metastatic NSCLC treated at NCCN institutions. J Natl Compr Canc
Netw. 10:847–856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blais N and Kassouf E: Maintenance
therapies for non-small cell lung cancer. Front Oncol. 4:2132014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
8
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim VN: MicroRNA biogenesis: Coordinated
cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shivdasani RA: MicroRNAs: Regulators of
gene expression and cell differentiation. Blood. 108:3646–3653.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cao Q, Mao ZD, Shi YJ, Chen Y, Sun Y,
Zhang Q, Song L and Peng LP: MicroRNA-7 inhibits cell
proliferation, migration and invasion in human non-small cell lung
cancer cells by targeting FAK through ERK/MAPK signaling pathway.
Oncotarget. 7:77468–77481. 2016.PubMed/NCBI
|
|
12
|
Zhu X, Li Y, Shen H, Li H, Long L, Hui L
and Xu W: miR-137 inhibits the proliferation of lung cancer cells
by targeting Cdc42 and Cdk6. FEBS Lett. 587:73–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dou C, Wang Y, Li C, Liu Z, Jia Y, Li Q,
Yang W, Yao Y, Liu Q and Tu K: MicroRNA-212 suppresses tumor growth
of human hepatocellular carcinoma by targeting FOXA1. Oncotarget.
6:13216–13228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding G, Zhou L, Qian Y, Fu M, Chen J, Chen
J, Xiang J, Wu Z, Jiang G and Cao L: Pancreatic cancer-derived
exosomes transfer miRNAs to dendritic cells and inhibit RFXAP
expression via miR-212-3p. Oncotarget. 6:29877–29888. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramalinga M, Roy A, Srivastava A,
Bhattarai A, Harish V, Suy S, Collins S and Kumar D: MicroRNA-212
negatively regulates starvation induced autophagy in prostate
cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis
and cellular senescence. Oncotarget. 6:34446–34457. 2015.PubMed/NCBI
|
|
16
|
Luo XJ, Tang DG, Gao TL, Zhang YL, Wang M,
Quan ZX and Chen J: MicroRNA-212 inhibits osteosarcoma cells
proliferation and invasion by down-regulation of Sox4. Cell Physiol
Biochem. 34:2180–2188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hanieh H: Aryl hydrocarbon
receptor-microRNA-212/132 axis in human breast cancer suppresses
metastasis by targeting SOX4. Mol Cancer. 14:1722015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li D, Li Z, Xiong J, Gong B, Zhang G, Cao
C, Jie Z, Liu Y, Cao Y, Yan Y, et al: MicroRNA-212 functions as an
epigenetic-silenced tumor suppressor involving in tumor metastasis
and invasion of gastric cancer through down-regulating PXN
expression. Am J Cancer Res. 5:2980–2997. 2015.PubMed/NCBI
|
|
19
|
Liu H, Li C, Shen C, Yin F, Wang K, Liu Y,
Zheng B, Zhang W, Hou X, Chen X, et al: MiR-212-3p inhibits
glioblastoma cell proliferation by targeting SGK3. J Neurooncol.
122:431–439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H,
Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic
cancer cell growth and invasion by targeting the hedgehog signaling
pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi B, Liu SG, Qin XG, Yao WJ, Lu JG, Guo
L, Wang TY, Li HC and Zhao BS: Overregulation of microRNA-212 in
the poor prognosis of esophageal cancer patients. Genet Mol Res.
13:7800–7807. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Zhang D, Chen C, Ruan Z, Li Y and
Huang Y: MicroRNA-212 displays tumor-promoting properties in
non-small cell lung cancer cells and targets the hedgehog pathway
receptor PTCH1. Mol Biol Cell. 23:1423–1434. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu L and Zhang X, Zhang B, Wu J and Zhang
X: Synaptic acetylcholinesterase targeted by microRNA-212 functions
as a tumor suppressor in non-small cell lung cancer. Int J Biochem
Cell Biol. 45:2530–2540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao JL, Zhang L, Guo X, Wang JH, Zhou W,
Liu M, Li X and Tang H: miR-212/132 downregulates SMAD2 expression
to suppress the G1/S phase transition of the cell cycle and the
epithelial to mesenchymal transition in cervical cancer cells.
IUBMB Life. 67:380–394. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wada R, Akiyama Y, Hashimoto Y, Fukamachi
H and Yuasa Y: miR-212 is downregulated and suppresses
methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J
Cancer. 127:1106–1114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hatakeyama H, Cheng H, Wirth P, Counsell
A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough
WG, et al: Regulation of heparin-binding EGF-like growth factor by
miR-212 and acquired cetuximab-resistance in head and neck squamous
cell carcinoma. PLoS One. 5:e127022010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tu H, Wei G, Cai Q, Chen X, Sun Z, Cheng
C, Zhang L, Feng Y, Zhou H, Zhou B, et al: MicroRNA-212 inhibits
hepatocellular carcinoma cell proliferation and induces apoptosis
by targeting FOXA1. Onco Targets Ther. 8:2227–2235. 2015.PubMed/NCBI
|
|
29
|
Wu Z, Zhou L, Ding G and Cao L:
Overexpressions of miR-212 are associated with poor prognosis of
patients with pancreatic ductal adenocarcinoma. Cancer Biomark.
18:35–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Castillo SD, Matheu A, Mariani N,
Carretero J, Lopez-Rios F, Lovell-Badge R and Sanchez-Cespedes M:
Novel transcriptional targets of the SRY-HMG box transcription
factor SOX4 link its expression to the development of small cell
lung cancer. Cancer Res. 72:176–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bilir B, Osunkoya AO, Wiles WG IV,
Sannigrahi S, Lefebvre V, Metzger D, Spyropoulos DD, Martin WD and
Moreno CS: SOX4 is essential for prostate tumorigenesis initiated
by PTEN ablation. Cancer Res. 76:1112–1121. 2016. View Article : Google Scholar : PubMed/NCBI
|
